Regional Covid-19 Resources and On Reserve Stats by Region Below:
Black = New Cases, Green = Recovered, Red = Deaths, Blue – Hospitalized, Purple – ISC reported total –  Updated Daily

BC
45 359 131 6,662 7,220
AB
87 838 151 15,086 16,389
SK
52 425 111 14,129 14,546
MB
203 677 125 14,563 15,676
ON
265 215 61 6,040 7,031
QC
59 31 10 3,399 4,832
Atlantic
4 8 4 911 1,146
North60
49 156 34 6,923 8,654
 

Antivirals could be a pandemic game-changer — and they could be in Canada soon – CBC

Canada has placed orders with Pfizer, Merck for therapeutics that can be administered at home

Jan 14, 2022

As a pandemic-weary country confronts another wave of COVID-19 cases with a strained health care system, Health Canada is looking at new products that could offer some relief: antivirals.

Two such drugs are making their way through the labyrinthine Health Canada approvals process: Pfizer’s Paxlovid and Merck’s molnupiravir.

These antiviral treatments, which are prescribed by a doctor and administered in pill form, are designed to help the body fight off the SARS-CoV-2 virus, reduce symptoms from an infection and shorten the period of illness.

While Merck has grappled with questions about the efficacy of its product — molnupiravir is said to reduce hospitalization or death by 30 per cent — Paxlovid earned especially high marks in testing.

After a months-long study, Pfizer reported in November that Paxlovid reduced the risk of hospitalization or death by an impressive 89 per cent compared to a placebo in non-hospitalized high-risk adults with COVID-19.

Read more: https://www.cbc.ca/news/politics/game-changing-covid-antivirals-canada-soon-1.6314214

NationTalk Partners & Sponsors Learn More